India, U.S. Groups To Partner For Gene-Based Cancer Drug
This article was originally published in PharmAsia News
Executive Summary
India's Council of Scientific and Industrial Research has signed an agreement with a U.S. university to combine the abilities of India's researchers in biochemistry and genetics with making diagnostics techniques based on genomics. One of the genome pioneers predicts all anatomical pathology tests will be replaced by molecular testing within 20 years. The CSIR agreement with the University of California at Berkeley is to produce the drug vincristine to treat cancer in a new way by combining Indian expertise with UCB's engineering knowledge. Indians are to clone genes from artemisinin and Americans are to build molecular pathways for the drug inside organisms. (Click here for more
|
India's Council of Scientific and Industrial Research has signed an agreement with a U.S. university to combine the abilities of India's researchers in biochemistry and genetics with making diagnostics techniques based on genomics. One of the genome pioneers predicts all anatomical pathology tests will be replaced by molecular testing within 20 years. The CSIR agreement with the University of California at Berkeley is to produce the drug vincristine to treat cancer in a new way by combining Indian expertise with UCB's engineering knowledge. Indians are to clone genes from artemisinin and Americans are to build molecular pathways for the drug inside organisms. (Click here for more) "Indian Scientists To Partner In Making Genetic Cancer Drug" - Livemint (India) (9/29/08) |